[go: up one dir, main page]

HK1217715A1 - 治療中風的組合物及方法 - Google Patents

治療中風的組合物及方法 Download PDF

Info

Publication number
HK1217715A1
HK1217715A1 HK16105676.2A HK16105676A HK1217715A1 HK 1217715 A1 HK1217715 A1 HK 1217715A1 HK 16105676 A HK16105676 A HK 16105676A HK 1217715 A1 HK1217715 A1 HK 1217715A1
Authority
HK
Hong Kong
Prior art keywords
stroke
ischemic stroke
methods
treatment
acute
Prior art date
Application number
HK16105676.2A
Other languages
English (en)
Inventor
Barry Ticho
Jacob Elkins
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of HK1217715A1 publication Critical patent/HK1217715A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16105676.2A 2013-07-05 2014-07-03 治療中風的組合物及方法 HK1217715A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843125P 2013-07-05 2013-07-05
US61/843,125 2013-07-05
PCT/US2014/045457 WO2015003156A1 (en) 2013-07-05 2014-07-03 Compositions and methods for treatment of stroke

Publications (1)

Publication Number Publication Date
HK1217715A1 true HK1217715A1 (zh) 2017-01-20

Family

ID=52144219

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105676.2A HK1217715A1 (zh) 2013-07-05 2014-07-03 治療中風的組合物及方法

Country Status (13)

Country Link
US (1) US20160152709A1 (zh)
EP (1) EP3016981A4 (zh)
JP (1) JP2016523931A (zh)
KR (1) KR20160030200A (zh)
CN (1) CN105658667A (zh)
AU (1) AU2014285086A1 (zh)
CA (1) CA2916028A1 (zh)
EA (1) EA201690170A1 (zh)
HK (1) HK1217715A1 (zh)
IL (1) IL243265A0 (zh)
MX (1) MX2015017467A (zh)
WO (1) WO2015003156A1 (zh)
ZA (1) ZA201509360B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007267579B2 (en) * 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
US20200255530A1 (en) * 2015-07-23 2020-08-13 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2018140510A1 (en) * 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273614B1 (ko) * 2004-07-08 2013-06-12 엘란 파마슈티칼스, 인크. 중합체 부분을 포함하는 다가 ｖｌａ―４ 길항제
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
AU2007267579B2 (en) * 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
US8771689B2 (en) * 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
EP2050462A1 (en) * 2007-10-18 2009-04-22 PAION Deutschland GmbH Improved treatment of stroke patients
EP3202789B1 (en) * 2010-04-16 2020-05-06 Biogen MA Inc. Anti-vla-4 antibodies
EP2769222A1 (en) * 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Methods of risk assessment of pml and related apparatus

Also Published As

Publication number Publication date
EA201690170A1 (ru) 2016-05-31
EP3016981A1 (en) 2016-05-11
EP3016981A4 (en) 2017-05-31
CN105658667A (zh) 2016-06-08
US20160152709A1 (en) 2016-06-02
WO2015003156A1 (en) 2015-01-08
MX2015017467A (es) 2016-04-25
IL243265A0 (en) 2016-03-31
KR20160030200A (ko) 2016-03-16
ZA201509360B (en) 2018-07-25
CA2916028A1 (en) 2015-01-08
AU2014285086A1 (en) 2016-01-21
JP2016523931A (ja) 2016-08-12

Similar Documents

Publication Publication Date Title
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
HK1252978A1 (zh) 用於治療神經肌肉病癥的化合物
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
WO2015028969A3 (en) Transduction buffer
WO2016011306A3 (en) Terminal modifications of polynucleotides
PH12019550235A1 (en) Kinase inhibitors and uses thereof
WO2017060475A3 (en) Polypeptides
WO2015085318A3 (en) Targeted adaptive vaccines
WO2015073587A3 (en) Synthetic membrane-receiver complexes
HK1220355A1 (zh) Mk2抑制劑和其用途
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
WO2015011694A3 (en) Isotopologues of smad7 antisense oligonucleotides
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
WO2015127134A3 (en) Complement component c5 antibodies
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2014150925A3 (en) Deuterated palbociclib
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
WO2015029074A3 (en) Compositions of eltrombopag
WO2015092810A3 (en) Amorphous form of idelalisib
WO2016001885A3 (en) Amorphous form of eliglustat hemitartarate
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
HK1217715A1 (zh) 治療中風的組合物及方法
PH12014502351A1 (en) Methods of producing anamorelin hydrochloride having controlled chloride content